The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
Researchers examined DNA methylation and chromatin accessibility in preimplantation embryos using single-cell chromatin overall omic-scale landscape sequencing.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
Researchers found that individuals with unexplained neurodevelopmental disorders and congenital anomalies had an enrichment of de novo epivariations.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The Epigenetics For Female Personalised Cancer Care (EpiFemCare) project recently published its findings in two papers in the journal Genome Medicine.
The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.
The Salk Institute-led team developed a system for in vivo activation of endogenous target genes through trans-epigenetic remodeling.
In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.
At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.
The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.
Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.